Results 211 to 220 of about 632,681 (338)
ABSTRACT Objective Onasemnogene abeparvovec (OA) is an AAV9‐based gene therapy for spinal muscular atrophy type I (SMA I). Real‐world outcomes show increased response variability compared to clinical trials, and follow‐up data beyond 12–18 months are limited.
Marika Pane +43 more
wiley +1 more source
Tight Approximation and Kernelization Bounds for Vertex-Disjoint Shortest Paths. [PDF]
Bentert M, Fomin FV, Golovach PA.
europepmc +1 more source
WEIGHTED APPROXIMATIONS BY POLYNOMIALS IN LP[Q] [PDF]
Grażyna Kozlowska
openalex +1 more source
Quantifying the Impact of Ocrelizumab on Paramagnetic Rim Lesions in Multiple Sclerosis
ABSTRACT Paramagnetic rim lesions (PRLs) are a subset of chronic active multiple sclerosis (MS) lesions marked by iron‐laden microglia and macrophages. Ocrelizumab, a monoclonal antibody targeting CD20+ B cells, suppresses acute MS activity, but its effect on PRLs remains unclear. In a longitudinal study of 29 ocrelizumab‐treated patients with at least
Kimberly H. Markowitz +9 more
wiley +1 more source
31P MRSI Coil Combination Using 23Na Sensitivity Information. [PDF]
Dai J +5 more
europepmc +1 more source
A convex approximation approach to Weighted Sum Rate Maximization of Multiuser MISO Interference Channel under outage constraints [PDF]
Tsung-Che Chiang +3 more
openalex +1 more source
ABSTRACT Objective This analysis evaluates the effect of successful reperfusion on functional outcomes after MT, stratified by admission National Institutes of Health Stroke Scale (NIHSS) and Alberta Stroke Program Early CT Score (ASPECTS) as surrogates for clinical‐core mismatch, using multicenter registry data.
Felix Schlicht +53 more
wiley +1 more source
Discrete stochastic maximal regularity. [PDF]
Evangelopoulos-Ntemiris F, Veraar M.
europepmc +1 more source

